To validate whether our findings in cell line xenografts are representative of primary SMARCA4-UT tumors in patients, we initially made use of a YAP1 signature, previously used to interrogated YAP1 expression in SCLC Circulating Tumor Xenograft (CTX) models (10). The gene discussed is SMARCA4; the disease is neoplasm.